











**TABLE 2. Antiandrogen activity of phenothiazine derivatives as determined by inhibition of DHT-stimulated CAT activity**

<i>D1</i>	<i>D2</i>	<i>D3</i>	<i>D4</i>
 <p><b>AR(-) = 9.0 ± 0.5%*</b></p>	 <p><b>AR(-) = 2.4 ± 0.5%</b></p>	 <p><b>AR(-) = 2.8 ± 0.1%</b></p>	 <p><b>AR(-) = 53.0 ± 0.7%</b></p>
<i>D5</i>	<i>D6</i>	<i>D7</i>	<i>D8</i>
 <p><b>AR(-) = n/a</b></p>	 <p><b>AR(-) = n/a</b></p>	 <p><b>AR(-) = 11.9 ± 0.2%</b></p>	 <p><b>AR(-) = n/a</b></p>
<i>D9</i>	<i>D10</i>		
 <p><b>AR(-) = n/a</b></p>	 <p><b>AR(-) = 2.4 ± 0.2%</b></p>		

The data are mean ± SEM of triplicate; n/a, no significant antagonism was observed.

\*antiandrogen activity is expressed as degree of inhibition of the reporter gene transactivation by 500 nM of indicated ligand in the presence of 1 nM DHT.